Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)

AIM: To assess what drives change in health‐related quality of life (HRQoL) in type 2 diabetes in the SUSTAIN 6 trial and identify potential mediators of the treatment effect of semaglutide on HRQoL scores. MATERIALS AND METHODS: The Short Form (SF)‐36v2® questionnaire [comprising physical component...

Descripción completa

Detalles Bibliográficos
Autores principales: Jódar, Esteban, Michelsen, Marie, Polonsky, William, Réa, Rosangela, Sandberg, Anna, Vilsbøll, Tina, Warren, Mark, Harring, Signe, Ziegler, Uwe, Bain, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383680/
https://www.ncbi.nlm.nih.gov/pubmed/32227613
http://dx.doi.org/10.1111/dom.14039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383680/
https://www.ncbi.nlm.nih.gov/pubmed/32227613
http://dx.doi.org/10.1111/dom.14039

Ejemplares similares